Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

Effects of GLP-1R agonist or co-cyprindiol, in combination with metformin, on polycystic ovary syndrome in overweight women: A Randomized Clinical Trial
  • +11
  • Mingyu Liao,
  • Xing Li,
  • Hao Zhang,
  • Ling Zhou ,
  • Liu Shi,
  • Weixin Li,
  • Rufei Shen ,
  • Guiliang Peng ,
  • Huan Zhao,
  • Jiaqing Shao ,
  • Xiujie Wang,
  • Zheng Sun,
  • Hongting Zheng ,
  • Min Long
Mingyu Liao
Third Military Medical University Second Affiliated Hospital

Corresponding Author:[email protected]

Author Profile
Xing Li
Medical School of Nanjing University
Author Profile
Hao Zhang
Chinese Academy of Sciences
Author Profile
Ling Zhou
Third Military Medical University Second Affiliated Hospital
Author Profile
Liu Shi
Third Military Medical University Second Affiliated Hospital
Author Profile
Weixin Li
Third Military Medical University Second Affiliated Hospital
Author Profile
Rufei Shen
Third Military Medical University Second Affiliated Hospital
Author Profile
Guiliang Peng
Third Military Medical University Second Affiliated Hospital
Author Profile
Huan Zhao
Third Military Medical University Second Affiliated Hospital
Author Profile
Jiaqing Shao
Medical School of Nanjing University
Author Profile
Xiujie Wang
Chinese Academy of Sciences
Author Profile
Zheng Sun
Baylor College of Medicine
Author Profile
Hongting Zheng
Third Military Medical University Second Affiliated Hospital
Author Profile

Abstract

Objective:Polycystic ovary syndrome (PCOS) is characterized by reproductive dysfunctions and metabolic disorders. This study aims to compare the therapeutic effectiveness of glucagon-like peptide-1 receptor agonist (GLP-1RA) + Metformin (Met) versus co-cyprindiol (cyproterone acetate/ethinylestradiol, CPA/EE) + Met in overweight PCOS women and identify potential biomarkers. Methods: In this prospective, open-label randomized controlled trial, we recruited 60 overweight PCOS women into two groups at a 1:1 ratio to receive CPA/EE (2 mg/day) + Met (1,500 mg/day) or GLP-1RA (liraglutide, 0.6-1.2 mg/day) + Met (1,500 mg/day) for 12 weeks. The clinical effectiveness and adverse effects were evaluated, followed by plasma proteomic analysis and verification of critical biomarkers by ELISA. Results: Both interventions improved menstrual cycle, polycystic ovaries, LH levels, and LH/FSH ratio; meanwhile reduced the body weight, BMI, HbA1c, FBG, OGTT-30 min insulin, IL-6 and TNF-α. Whereas, GLP-1RA + Met showed a more robust improvement on HbA1c, HOMA-IR, lipid profiles, inflammatory parameters, and ovulation. CPA/EE + Met was more effective in reducing hyperandrogenemia. Plasma proteomic analysis revealed that the interventions altered proteins involved in reactive oxygen species detoxification (PRDX6, GSTO1, GSTP1, GSTM2), platelet degranulation (FN1), and the immune response (SERPINB9). Conclusions: CPA/EE+Met or GLP-1RA + Met treatment improved reproductive functions and alleviated metabolic disorders in overweight PCOS women. GLP-1RA + Met had a superior improvement in metabolism and inflammation. The novel plasma biomarkers PRDX6, FN1, and SERPINB9, might be indicators and targets for PCOS treatment.